TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC

Cardiovasc Intervent Radiol. 2022 Nov;45(11):1599-1607. doi: 10.1007/s00270-022-03072-8. Epub 2022 Feb 11.


The Barcelona Clinic Liver Cancer (BCLC) system is the most commonly used staging system for hepatocellular carcinoma (HCC) in Western countries. BCLC aims to categorize patients into five stages with different prognoses and to allocate treatment according to these stages based on the best possible contemporary evidence. Transarterial radioembolization (TARE) has recently entered at the left of the BCLC algorithm (i.e., BCLC 0-A), mainly because of negative phase III trials in BCLC C stage. TARE has shown a steady increase in nationwide studies over the past 20 years and has even been adopted in some tertiary centers as the primary HCC treatment across all BCLC stages. We aimed to review the history of TARE in HCC, starting from advanced HCC and gradually expanding to earlier stages at the left of the BCLC system.

Keywords: Dosimetry; Liver cancer; Radioembolization; Yttrium.

Publication types

  • Review

MeSH terms

  • Brachytherapy*
  • Carcinoma, Hepatocellular* / therapy
  • Embolization, Therapeutic*
  • Humans
  • Liver Neoplasms* / therapy
  • Neoplasm Staging
  • Retrospective Studies
  • Yttrium Radioisotopes


  • Yttrium Radioisotopes